Supplementary Table 2. Prespecified Outcomes , for Recombinant Zoster Vaccine (RZV) in Reports Submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Supplementary Table 2. Prespecified Outcomes , for Recombinant Zoster Vaccine (RZV) in Reports Submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018

February 1, 2019
Source: MMWR: Morbidity and Mortality Weekly Report 2019; v. 68, no. 4
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

English

Details Supporting Files Related Documents You May Also Like

Details:

Alternative Title:

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018: Supplementary Table 2. Prespecified Outcomes , for Recombinant Zoster Vaccine (RZV) in Reports Submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
Description:

Supplementary Table for: Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018.
Source:

MMWR: Morbidity and Mortality Weekly Report 2019; v. 68, no. 4
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Document Type:

Journal Article
Genre:

Tables
Place as Subject:

United States
Volume:

68
Issue:

4
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:c1a9d6907ab0ea2792c4631aecbcc56512d1c6a8a6f8c2bc17a69eb1f8666a71b6963ea0e1cdbdf94c1bf74c5b7ff2672610399432e91a2c410655d811b5d295
Download URL:

https://stacks.cdc.gov/view/cdc/62215/cdc_62215_DS1.pdf
File Type:

[PDF-68.84 KB]

VAERS - Shingrix safety surveillance SUPPLEMENTARY TABLE 2.docx

docx